Generation of autologous tumor-speciWc T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion

Cancer Immunology, Immunotherapy

Volumn 61, Issue 8, 2012, Pages 1221-1231

  Brimnes, Marie Klinge ^a   Gang, Anne Ortved ^a   Donia, Marco ^a,b   Straten, Perthor ^a   Svane, Inge Marie ^a   Hadrup, Sine Reker ^a,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adoptive T cell therapy; Dynabeads ClinExVivo CD3 CD28; T cell expansion; Tumor speciWc T cells

Indexed keywords

CD137 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; DENDRITIC CELL VACCINE;

ADOPTIVE TRANSFER; ANTIGEN RECOGNITION; ARTICLE; CELL EXPANSION; CELL ISOLATION; CELL SPECIFICITY; CELL TRANSFER; CELLULAR IMMUNITY; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE MIGRATION; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TELOMERE; VACCINATION;

ANTIGENS, CD28; ANTIGENS, CD3; CANCER VACCINES; CELL CULTURE TECHNIQUES; CLINICAL TRIALS AS TOPIC; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTES;

EID: 84865768316     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1199-8     Document Type: Article

References (38)

1. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-915 (Pubitemid 39273730)
2. Donia M, Junker N, Ellebaek E, Andersen MH, Straten PT, Svane IM (2011) Characterization and comparison of "standard" and "young" tumor inWltrating lymphocytes for adoptive cell therapy at a Danish Translational Research Institution. Scand J Immunol [Epub ahead of print]
3. Rosenberg SA, Dudley ME (2009) Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21:233-240
4. Blattman JN, Greenberg PD (2004) Cancer immunotherapy: A treatment for the masses. Science 305:200-205 (Pubitemid 38886725)
5. Pure E, Allison JP, Schreiber RD (2005) Breaking down the barriers to cancer immunotherapy. Nat Immunol 6:1207-1210 (Pubitemid 43045629)
6. Neurauter AA, Bonyhadi M, Lien E et al (2007) Cell isolation and expansion using Dynabeads. Adv Biochem Eng Biotechnol 106:41-73
7. Porter DL, Levine BL, Bunin N et al (2006) A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 107:1325-1331 (Pubitemid 43242365)
8. Rapoport AP, Stadtmauer EA, Aqui N et al (2005) Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 11:1230-1237 (Pubitemid 43093671)
9. Rapoport AP, Stadtmauer EA, Aqui N et al (2009) Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin Cancer Res 15:4499-4507
10. Rapoport AP, Aqui NA, Stadtmauer EA et al (2011) Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 117:788-797
11. Thompson JA, Figlin RA, Sifri-Steele C, Berenson RJ, Frohlich MW (2003) A phase I trial of CD3/CD28-Activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res 9:3562-3570 (Pubitemid 37169219)
12. Dang Y, Knutson KL, Goodell V et al (2007) Tumor antigen-speciWc T-cell expansion is greatly facilitated by in vivo priming. Clin Cancer Res 13:1883-1891 (Pubitemid 46952959)
13. Rasmussen AM, Borelli G, Hoel HJ et al (2010) Ex vivo expansion protocol for human tumor speciWc T cells for adoptive T cell therapy. J Immunol Methods 355:52-60
14. Trepiakas R, Berntsen A, Hadrup SR et al (2010) Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy 12:721-734
15. Berntsen A, Trepiakas R, Wenandy L et al (2008) Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: A clinical phase 1/2 trial. J Immunother 31:771-780
16. Toebes M, Coccoris M, Bins A et al (2006) Design and use of conditional MHC class I ligands. Nat Med 12:246-251 (Pubitemid 43214754)
17. Rodenko B, Toebes M, Hadrup SR et al (2006) Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc 1:1120-1132
18. Andersen MH, BonWll JE, Neisig A et al (1999) Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-speciWc CTL. J Immunol 163:3812-3818 (Pubitemid 29450906)
19. Kapoor V, Hakim FT, Rehman N, Gress RE, Telford WG (2009) Quantum dots thermal stability improves simultaneous phenotypespeciWc telomere length measurement by FISH-Xow cytometry. J Immunol Methods 344:6-14
20. Batliwalla FM, Damle RN, Metz C, Chiorazzi N, Gregersen PK (2001) Simultaneous Xow cytometric analysis of cell surface markers and telomere length: Analysis of human tonsilar B cells. J Immunol Methods 247:103-109 (Pubitemid 32057048)
21. Schmid I, Dagarag MD, Hausner MA et al (2002) Simultaneous Xow cytometric analysis of two cell surface markers, telomere length, and DNA content. Cytometry 49:96-105 (Pubitemid 41202161)
22. Schmid I, Jamieson BD (2004) Assessment of telomere length, phenotype, and DNA content. Curr Protoc Cytom Chapter 7:Unit 7.26
23. Hadrup SR, Toebes M, Rodenko B et al (2009) High-Throughput T-cell epitope discovery through MHC peptide exchange. Methods Mol Biol 524:383-405
24. Dudley ME, Wunderlich JR, Yang JC et al (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346-2357 (Pubitemid 46218728)
25. Dudley ME, Yang JC, Sherry R et al (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233-5239
26. Dudley ME, Gross CA, Langhan MM et al (2010) CD8+ enriched "young" tumor inWltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 16:6122-6131
27. Robbins PF, Morgan RA, Feldman SA et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NYESO- 1. J Clin Oncol 29:917-924
28. Rosenberg SA, Yang JC, Robbins PF et al (2003) Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother 26:385-393 (Pubitemid 37128550)
29. Dudley ME, Wunderlich JR, Robbins PF et al (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854 (Pubitemid 35231542)
30. Pawelec G (2004) Tumour escape: Antitumour eVectors too much of a good thing? Cancer Immunol Immunother 53:262-274 (Pubitemid 38328050)
31. ButterWeld LH, Ribas A, Dissette VB et al (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9:998- 1008 (Pubitemid 36323703)
32. Rini BI, Eisen T, Stenzl A et al IMA901 Multipeptide vaccine randomized international phase III trial (IMPRINT): A randomized, controlled study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as Wrst-line therapy for advanced/metastatic RCC. [abstract]
33. Rini BI, Eisen T, Stenzl A et al. ASCO Annual Meeting 2011; Abstract No: TPS183
34. Ghosh A, Wolenski M, Klein C, Welte K, Blazar BR, Sauer MG (2008) Cytotoxic T cells reactive to an immunodominant leukemia- associated antigen can be speciWcally primed and expanded by combining a speciWc priming step with nonspeciWc large-scale expansion. J Immunother 31:121-131
35. Hami LS, Green C, Leshinsky N, Markham E, Miller K, Craig S (2004) GMP production and testing of Xcellerated T cells for the treatment of patients with CLL. Cytotherapy 6:554-562 (Pubitemid 40028914)
36. Kalamasz D, Long SA, Taniguchi R, Buckner JH, Berenson RJ, Bonyhadi M (2004) Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti- CD28 antibodies. J Immunother 27:405-418 (Pubitemid 39121930)
37. Shen X, Zhou J, Hathcock KS et al (2007) Persistence of tumor inWltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother 30:123-129 (Pubitemid 46052211)
38. Rufer N, Migliaccio M, Antonchuk J, Humphries RK, Roosnek E, Lansdorp PM (2001) Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood 98:597-603